Literature DB >> 33835295

The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer.

Isamu Hoshino1.   

Abstract

MicroRNA (miR) is a type of short non-coding RNA comprising 21-25 nucleotides. While it has been researched widely, its relationship with cancer was clarified recently and it was found to play a significant role in the development and progression of cancer. Furthermore, miR can remain stable for relatively long periods in the blood by being present in exosomes (extracellular microvesicles) or by forming a complex with the Ago2 protein, which gives rise to cancer-specific miR. It is known that miR can indicate the presence and extent of cancer progression. Several reports have proved that miR in urine and saliva is detected in urinary and oral cancer, respectively, and recent studies have also shown it to be present in cases of gastroenterological cancer, showing evidence of it being a biomarker for cancer. To gather further knowledge on this topic, this review aims to summarize the usefulness of urinary and salivary miR as a biomarker for gastroenterological cancer and discuss its existence, stability mechanism, and direction of future research. The findings will be relevant for physicians and oncologists who routinely treat patients with gastric cancers.

Entities:  

Keywords:  Exosome; Gastroenterological cancer; MicroRNA; Saliva; Serum; Urine; miR

Year:  2021        PMID: 33835295     DOI: 10.1007/s10147-021-01911-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  66 in total

Review 1.  The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.

Authors:  Lynette M Sholl; Fred R Hirsch; David Hwang; Johan Botling; Fernando Lopez-Rios; Lukas Bubendorf; Mari Mino-Kenudson; Anja C Roden; Mary Beth Beasley; Alain Borczuk; Elisabeth Brambilla; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Wendy A Cooper; Sanja Dacic; Sylvie Lantuejoul; Deepali Jain; Dongmei Lin; Yuko Minami; Andre Moreira; Andrew G Nicholson; Masayuki Noguchi; Mauro Papotti; Giuseppe Pelosi; Claudia Poleri; Natasha Rekhtman; Ming-Sound Tsao; Erik Thunnissen; William Travis; Yasushi Yatabe; Akihiko Yoshida; Jillian B Daigneault; Ahmet Zehir; Solange Peters; Ignacio I Wistuba; Keith M Kerr; John W Longshore
Journal:  J Thorac Oncol       Date:  2020-06-06       Impact factor: 15.609

Review 2.  Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Authors:  Michail Ignatiadis; Brigitte Rack; Francoise Rothé; Sabine Riethdorf; Charles Decraene; Hervé Bonnefoi; Christian Dittrich; Carlo Messina; Melanie Beauvois; Elisabeth Trapp; Theodora Goulioti; Konstantinos Tryfonidis; Klaus Pantel; Madeline Repollet; Wolfgang Janni; Martine Piccart; Christos Sotiriou; Saskia Litiere; Jean-Yves Pierga
Journal:  Eur J Cancer       Date:  2016-06-10       Impact factor: 9.162

Review 3.  Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice.

Authors:  Charu Aggarwal; Christian D Rolfo; Geoffrey R Oxnard; Jhanelle E Gray; Lynette M Sholl; David R Gandara
Journal:  Nat Rev Clin Oncol       Date:  2020-09-11       Impact factor: 66.675

Review 4.  Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.

Authors:  Maryam B Lustberg; Daniel G Stover; Jeffrey J Chalmers
Journal:  Cancer J       Date:  2018 Mar/Apr       Impact factor: 3.360

Review 5.  MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors:  Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

6.  Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Authors:  Thomas Melchardt; Teresa Magnes; Clemens Hufnagl; Aaron R Thorner; Matthew Ducar; Daniel Neureiter; Wolfgang Tränkenschuh; Eckhard Klieser; Alexander Gaggl; Sebastian Rösch; Gerd Rasp; Tanja N Hartmann; Lisa Pleyer; Gabriel Rinnerthaler; Lukas Weiss; Richard Greil; Alexander Egle
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

7.  Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.

Authors:  Bing Wei; Chengzhi Zhao; Jun Li; Jiuzhou Zhao; Pengfei Ren; Ke Yang; Chi Yan; Rui Sun; Jie Ma; Yongjun Guo
Journal:  Mol Oncol       Date:  2019-04-10       Impact factor: 6.603

8.  Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

Authors:  Marianna Alunni-Fabbroni; Kerstin Rönsch; Thomas Huber; Clemens C Cyran; Max Seidensticker; Julia Mayerle; Maciej Pech; Bristi Basu; Chris Verslype; Julia Benckert; Peter Malfertheiner; Jens Ricke
Journal:  J Transl Med       Date:  2019-10-01       Impact factor: 5.531

Review 9.  Liquid biopsies and cancer omics.

Authors:  Ivano Amelio; Riccardo Bertolo; Pierluigi Bove; Oreste Claudio Buonomo; Eleonora Candi; Marcello Chiocchi; Chiara Cipriani; Nicola Di Daniele; Carlo Ganini; Hartmut Juhl; Alessandro Mauriello; Carla Marani; John Marshall; Manuela Montanaro; Giampiero Palmieri; Mauro Piacentini; Giuseppe Sica; Manfredi Tesauro; Valentina Rovella; Giuseppe Tisone; Yufang Shi; Ying Wang; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-11-26

10.  Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.

Authors:  John Malcolm Nicholls; Victor Ho-Fun Lee; Sik-Kwan Chan; Ka-Chun Tsang; Cheuk-Wai Choi; Dora Lai-Wan Kwong; Ka-On Lam; Sum-Yin Chan; Chi-Chung Tong; Tsz-Him So; To-Wai Leung; Mai-Yee Luk; Pek-Lan Khong; Anne Wing-Mui Lee
Journal:  Br J Cancer       Date:  2019-09-17       Impact factor: 7.640

View more
  3 in total

Review 1.  Non-coding RNAs as liquid biopsy biomarkers in cancer.

Authors:  Shusuke Toden; Ajay Goel
Journal:  Br J Cancer       Date:  2022-01-10       Impact factor: 7.640

Review 2.  Clinical Value and Molecular Function of Circulating MicroRNAs in Endometrial Cancer Regulation: A Systematic Review.

Authors:  Joy Bloomfield; Michèle Sabbah; Mathieu Castela; Céline Mehats; Catherine Uzan; Geoffroy Canlorbe
Journal:  Cells       Date:  2022-06-03       Impact factor: 7.666

3.  Association between the Expression Levels of MicroRNA-101, -103, and -29a with Autotaxin and Lysophosphatidic Acid Receptor 2 Expression in Gastric Cancer Patients.

Authors:  Sara Tutunchi; Saeedeh Akhavan; Ghodratollah Panahi; Mina Zare; Amirnader Emami Razavi; Reza Shirkoohi
Journal:  J Oncol       Date:  2022-04-11       Impact factor: 4.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.